My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

uniQure N.V. - Ordinary Shares (NQ:QURE)

20.50 -1.87 (-8.36%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Via Benzinga

NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

November 04, 2025

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗

November 03, 2025

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket ↗

November 04, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 03, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Which stocks are moving on Monday? ↗

November 03, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Gold Edges Higher; ISM Manufacturing PMI Falls In October ↗

November 03, 2025

Via Benzinga

UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data ↗

November 03, 2025

UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

November 03, 2025

From The Schall Law Firm

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE

November 03, 2025

From The DJS Law Group

Via Business Wire

Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings ↗

November 03, 2025

Via Benzinga

Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy ↗

November 03, 2025

An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.

Via Investor's Business Daily

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

November 03, 2025

From uniQure Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Breakout Momentum Plays You Need to Know About ↗

October 23, 2025

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Via MarketBeat

Why Is Protalix BioTherapeutics Stock Falling On Friday? ↗

October 17, 2025

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.

Via Benzinga

Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet ↗

October 06, 2025

Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises selling some Dillard's (DDS).

Via Benzinga

QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop ↗

October 03, 2025

Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come.

Via MarketBeat

10 Health Care Stocks Whale Activity In Today's Session ↗

October 01, 2025

Via Benzinga

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

September 29, 2025

From uniQure Inc.

Via GlobeNewswire

Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide ↗

September 27, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

uniQure Announces Pricing of Upsized $300 Million Public Offering

September 25, 2025

From uniQure Inc.

Via GlobeNewswire

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street ↗

September 25, 2025

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.